Neuromodulation technology developer Neuros Medical filed an SEC Form D to confirm the sale of nearly $37 million in equity. Willoughby Hills, Ohio-based Neuros Medical made the first sale in the new notice offering on Oct. 27, 2020, and listed in the SEC filing that it does not intend for it to last longer than […]
Neuros Medical Inc.
Neuros Medical said it named Tom Wilder, the CEO who led Sequent Medical to a $280 million acquisition by Terumo Corp. (TYO:4543), to take the corner office. “Neuros Medical, with its patented Altius system high-frequency nerve block technology, has the opportunity to develop important therapy options for patients who experience significant pain as a result […]
Neuros Medical today said it raised $20 million in what it’s calling a Series AA round, pledging the proceeds to a pivotal study of its Altius neurostimulation technology. Cleveland-based Neuros said the round was led by U.S. Venture Partners and included prior backers Boston Scientific (NYSE:BSX) and JumpStart plus contributions from Aperture Venture Partners and Osage University Partners. Neuros […]
Neuros Medical Inc. said it received an investigational device exemption from the FDA to run a clinical trial of its Altrius implantable generator to treat chronic pain in amputees.
The Altius device, consisting of an electrode and a generator, uses Neuros Medical’s patented electrical nerve block technology to deliver high-frequency stimulation to the peripheral nervous system to block chronic pain.
Neuros recently received an investigational device exemption from the FDA to evaluate its chronic pain management system, the electrical nerve block, for use in amputee patients to manage pain in the residual limb.
Boston Scientific Corp. (NYSE:BSX) landed FDA clearance for its Incepta, Energen and Punctua cardiac implants to treat heart failure and sudden cardiac death.
To go along with the new defibrillator systems, the Natick, Mass.-based med-tech titan is providing an extended warranty for the Incepta and Energen family of defibrillators.
Stratatech Corp. won a $4.6 million grant to run a clinical trial from the National Institute of Diabetes & Digestive & Kidney Diseases.
The funds will support the first human study of Stratatech’s ExpressGraft Antimicrobial genetically engineered living skin substitute as a therapy for diabetic foot ulcers.
Neurotechnology startup Neuros Medical Inc. reported encouraging results from the first in-human study of its device that blocks pain for amputees.
The Willoughby, Ohio-based company said that four of five patients in the study reported that its device reduced their pain to “zero,” according to a statement from the company.
Neuros Medical Inc. added a medical device industry veteran to its board of directors.
Scott Drees joined the board as an independent director. The Willoughby, Ohio, company is developing a neurostimulation device that uses a pacemaker-sized generator and an electrode to stimulate nerves to block pain from amputations, sometimes called stump pain, without the use of drugs.